Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elanco Animal Health Incorporated (NYSE: ELAN) SEC filings page on Stock Titan provides organized access to the company’s U.S. regulatory disclosures. As an Indiana-incorporated public company in the pharmaceutical preparation manufacturing industry, Elanco files reports with the Securities and Exchange Commission under Commission File Number 001-38661.
Through this page, readers can review current and historical Forms 8-K and, when available, annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials. Elanco’s recent Form 8-K filings illustrate the range of topics covered in its SEC disclosures, including quarterly financial results and guidance, restructuring plans and workforce changes, amendments to credit agreements and receivables facilities, and participation in major investor events such as its Investor Day and healthcare conferences.
These filings provide detail on Elanco’s financial condition, capital structure and risk factors, as well as material contracts and strategic initiatives. For example, recent 8-Ks describe the Elanco Ascend restructuring program, expected cost savings, facility changes, and refinancing of term loan facilities, along with updates on leverage targets and cash flow expectations. Other filings outline amendments to securitization and credit agreements that affect the company’s direct financial obligations.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the significance of each filing. Investors can use the ELAN filings page to monitor new 8-Ks, as well as future 10-K and 10-Q reports, and to track how management’s strategic, financial and operational decisions are reflected in official SEC documents.
On 27 June 2025, Elanco Animal Health Inc. (ELAN) disclosed in a Form 4 that Executive Vice President of U.S. Pet Health & Global Digital Transformation Rajeev A. Modi received 98.9937 deferred stock units (DSUs) at a reference price of $14.29 under the company’s Executive Deferral and Stock Match Plan. Each DSU converts into one common share or its cash equivalent upon settlement after employment ends or in a predetermined future year. The award is classified as transaction code “A,” meaning it is a compensation grant rather than an open-market purchase. Modi now directly holds 6,460.6903 DSUs; no shares were sold or otherwise disposed. The grant is small—worth roughly $1.4 thousand—and does not materially alter insider ownership or the company’s share count, but it marginally reinforces management-shareholder alignment.
Elanco Animal Health Inc. (ELAN) – Form 4 insider filing
On 27 June 2025, President & CEO Jeffrey N. Simmons acquired 193.7887 deferred stock units (DSUs) under the company’s Executive Deferral and Stock Match Plan at a reference price of $14.29. Each DSU represents the right to receive either one common share or a cash equivalent upon settlement, which occurs after employment ends or in a pre-elected future year. Following the transaction, Simmons now beneficially owns 16,849.4516 DSUs, held directly.
The filing discloses no open-market purchases or sales; the units were issued as part of a compensation-related deferral program. The size of the award—worth roughly US$2.8 thousand based on the reference price—is immaterial relative to Elanco’s market capitalisation and Simmons’ existing holdings, but it does incrementally increase insider ownership.
Elanco Animal Health (NYSE:ELAN) filed an 8-K reporting a First Amendment to its Receivables Loan Agreement with Rabobank. The amendment extends the accounts-receivable securitization facility’s maturity from Aug 3 2026 to Jun 26 2028, keeps Elanco as performance guarantor, Elanco SPEAR LLC as borrower, and Elanco US as servicer.
The filing is deemed a material definitive agreement (Item 1.01) and a direct financial obligation/off-balance-sheet arrangement (Item 2.03). Financial amounts were not disclosed, but the longer tenor is expected to improve liquidity and refinancing flexibility. Investors should review Exhibit 10.1 for precise covenant changes.